What’s the big hurry, Novartis? Pharma giant scores a PRV shortcut for $130M
Novartis $NVS is moving up the ladder of Big Pharma companies with the most aggressive development groups in the industry. Today we learned that the Basel-based giant paid $130 million to buy a priority review voucher from Ultragenyx $RARE.
That figure marks a tick up from the last PRV deal for $125 million, helping set a market floor for a regulatory shortcut that has been valued (by AbbVie) as high as $350 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
